Business
BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications
SUNNYVALE, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment
About this update from Biocardia, Inc.
[{"type":"text","content":"SUNNYVALE, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the United States Patent Office has granted Patent Number 11,642,377: titled, “ Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications”, with a patent term that will expire in 2039. The patent specification details methods for selecting and expanding NK1R+ Mesenchymal Stem Cells (MSC) and their use to treat a number of diseases. The first allowed claim protects using these cells to treat cardiovascular disease, pain, rheumatoid arthritis, diabetes, stroke, asthma, pulmonary fibrosis, and aging. There are seventeen additional claims allowed in this patent issuance. “This has potential to be a breakthrough in mesenchymal stem cell therapeutic development,” said Peter Altman, PhD, BioCardia President and CEO. “Our team’s effort and understanding of disease and injury led us to recognize that Substance P (SP) is the first responder neuropeptide in defense, stress, repair, and survival systems. We believe that how stem cells respond to SP is a critical mechanism to injury and inflammation. As Neurokinin-1 (NK1) is the primary receptor for SP on the surface of many cells, we explored whether we could select mesenchymal stem cells expressing the receptor and then expand them to clinically meaningful dosage levels. With this patent issued today, BioCardia now holds rights in the United States to a compelling therapeutic approach that has promise to treat a wide range of diseases. We will be looking to partner development in areas beyond our current cardiopulmonary focus.” About Biocardia® BioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP™ autologous and NK1R+ allogeneic cell therapies are the Company’s biotherapeutic platforms that enable four product candidates in development. The CardiAMP Cell Therapy Heart Failure Trial investigational product has been granted Breakthrough designation by the FDA, has CMS reimbursement, and is supported financially by the Maryland Stem Cell Research Fund. The CardiAMP Chronic Myocardial Ischemia Trial als...